Impact on the Length of Stay in Incentive Spirometry and Pain in the Decompensation of Sickle Cell Disease: . (SPIDO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04041180|
Recruitment Status : Completed
First Posted : August 1, 2019
Last Update Posted : August 1, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
In this prospective observational study among sickle cell children aged 7 to 17 years, who face many experience of pain, pain will be assessed during incentive spirometry sessions. Then a relation between, inspiratory volume, pain and the length of hospital stay will be identified .
Currently, there is no scientific data regarding the correlation between acute pain during vaso-occlusive crisis, incentive spirometry and the impact on length of hospital stay. In fact, physiotherapist experience's in the pediatric department suggests that the pain expressed by the child is not always correlated with inspiratory capacity.
The absence of pain is one of the reasons for hospital discharge after decompensation in patients with sickle cell disease. However, no scientific study has linked incentive spirometry, pain and length of hospital stay.
Investigator assume that these children underestimate the real pain and its impact on breathing pattern, and presume that the maximal inspiratory volume during spirometry sessions will be a better reflect of pain than standard pain scale.
The aim of this study is to show that inspiratory volume would be a better indicator of discharge from hospitalization than actual pain scales.
|Condition or disease|
|Sickle Cell Disease Pediatric|
|Study Type :||Observational|
|Actual Enrollment :||25 participants|
|Official Title:||Incentive Spirometry and Pain in the Decompensation of Sickle Cell Disease: Impact on the Length of Stay. Prospective Observational Study|
|Actual Study Start Date :||November 6, 2018|
|Actual Primary Completion Date :||April 6, 2019|
|Actual Study Completion Date :||April 6, 2019|
- Number of day staying in the pediatric ward according to the maximal inspiratory capacities during incentive spirometry sessions. [ Time Frame: throught study completion, an overage of 24hours ]
- Correlation between pain level and maximal inspiratory capacity during incentive spirometry sessions. [ Time Frame: throught study completion, an overage of 24hours ]
- Correlation between the maximum inspiratory volume achieved during incentive spirometry and children's mobility (attitude and mobility items according to the EVENDOL scale). [ Time Frame: throught study completion, an overage of 24hours ]
- Correlation between the use of analgesic strategies and the inspiratory volume related to patients' size and age [ Time Frame: throught study completion, an overage of 24hours ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||7 Years to 17 Years (Child)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Sickle cell children aged 7 to 17 admitted to the pediatric ward
- Children receiving respiratory physiotherapy sessions under medical prescription
- Children hospitalized for more than 24 hours at the CHRO and benefiting from more than one physiotherapy session.
- Absence of opposition of one of the parents to the participation of their child in the study
- Absence of opposition of children able to understand the study
Non inclusion Criteria:
- Sickle cell children under the age of 7 or over 17
- Children with mental deficits
- Non-French-speaking parents
- Children receiving only one physiotherapy session and being hospitalized within 24 hours
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04041180
|Orléans, France, 45067|
|Principal Investigator:||Sandrine Sandrine PELLETIER||CHR d'Orléans|
Publications of Results:
|Responsible Party:||Centre Hospitalier Régional d'Orléans|
|Other Study ID Numbers:||
|First Posted:||August 1, 2019 Key Record Dates|
|Last Update Posted:||August 1, 2019|
|Last Verified:||July 2019|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Sickle cell disease
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn